Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Natural Killer Cell Receptor 2A (NKG2A)
- Target
- NKG2A
- Molecular classification
- Receptor, C-type lectin-like receptor, Type II membrane protein
01
Overview
Natural Killer Cell Receptor 2A (NKG2A), also known as CD159a, is an inhibitory immune checkpoint receptor primarily expressed on natural killer (NK) cells, natural killer T (NKT) cells, and subsets of CD8+ T cells. It forms a heterodimer with CD94 and interacts with HLA-E to deliver inhibitory signals, suppressing the cytotoxic activity of NK and T cells. NKG2A is being explored as a therapeutic target in cancer immunotherapy to enhance anti-tumor immunity by blocking its inhibitory function.
- Other names
- CD159aKLRC1NK cell receptor A
02
Mechanism of action
Blockade of NKG2A interaction with HLA-E to enhance anti-tumor immunity
03
Biological functions
Immune regulationInhibition of NK cell cytotoxicityInhibition of T cell cytotoxicityRegulation of cytokine secretion
04
Disease associations
CancerViral infectionsAutoimmune diseasesInflammatory diseasesParasite infectionsTransplant rejection
05
Safety considerations
Potential for increased autoimmunityRisk of cytokine release syndrome
06
Interacting drugs
Monalizumab
07
Biomarkers
HLA-E expression levelsNKG2A expression levels on immune cells
Beyond the preview
Go deeper on Natural Killer Cell Receptor 2A (NKG2A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Natural Killer Cell Receptor 2A (NKG2A).